<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Controversy surrounds whether the ratio of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (ApoB) to <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> A-I (ApoA-I) is the best <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> discriminator of CHD risk in non-diabetic populations, but the issue has never been investigated in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In 2,627 participants without known <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> in the Collaborative <z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> <z:mp ids='MP_0002055'>Diabetes</z:mp> Study, ApoB, ApoA-I, <z:chebi fb="1" ids="47774">LDL-cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDLC</z:chebi>) and <z:chebi fb="4" ids="47775">HDL-cholesterol</z:chebi> (<z:chebi fb="0" ids="47775">HDLC</z:chebi>) were assayed at baseline </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: There were 108 CHD and 59 <z:hpo ids='HP_0001297'>stroke</z:hpo> endpoints over 3.9 years </plain></SENT>
<SENT sid="3" pm="."><plain>The ApoB:A-I ratio at baseline was the <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> variable most closely predicting CHD risk both by comparison of the hazard ratio for a 1 SD change or tertiles of frequency distribution </plain></SENT>
<SENT sid="4" pm="."><plain>The areas under the receiver-operator curve for the ApoB:ApoA-I and the <z:chebi fb="0" ids="47774">LDLC</z:chebi> to <z:chebi fb="0" ids="47775">HDLC</z:chebi> [corrected] ratios, although not significantly different from each other, were greater (p = 0.0005 and p = 0.0125 respectively) than that of non-<z:chebi fb="0" ids="47775">HDLC</z:chebi>:<z:chebi fb="0" ids="47775">HDLC</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>The 27% decrease in the ApoB:ApoA-I ratio on <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> predicted a 32% (95% CI 5.4-51.2%) risk reduction in CHD, close to the 36% decrease observed </plain></SENT>
<SENT sid="6" pm="."><plain>Neither the ApoB:ApoA-I nor any other <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> concentration or ratio predicted the <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: Overall, the ApoB:ApoA-I ratio improved on the non-<z:chebi fb="0" ids="47775">HDLC</z:chebi>:<z:chebi fb="0" ids="47775">HDLC</z:chebi> ratio in predicting CHD, but, depending on the assessment chosen, its superiority over <z:chebi fb="0" ids="47774">LDLC</z:chebi>:<z:chebi fb="0" ids="47775">HDLC</z:chebi> may be marginal </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:chebi fb="0" ids="35664">statin</z:chebi>-induced decrease in <z:hpo ids='HP_0001297'>stroke</z:hpo> risk may not be <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> mediated </plain></SENT>
<SENT sid="9" pm="."><plain>TRIAL REGISTRATION: ClinicalTrials.gov NCT00327418 </plain></SENT>
<SENT sid="10" pm="."><plain>FUNDING: The study was supported by unrestricted grants from <z:mp ids='MP_0002055'>Diabetes</z:mp> UK, the Department of Health and Pfizer to the University of Manchester and to University College, London </plain></SENT>
</text></document>